A54145 is a complex of lipopeptide antibiotics produced by Streptomyces fradiae. A54145 factors are structurally related to daptomycin, with four modified amino acids, only one of which is present in daptomycin. We generated three mutants defective in lptJ, lptK or lptL, whose gene products are involved in the formation of hydroxy-Asn 3 (hAsn 3 ) and methoxy-Asp 9 (moAsp 9 ). Each of the mutants produced novel lipopeptides related to A54145 and the profiles allowed assignment of functions for those genes. We constructed strains carrying different combinations of these genes coupled with a mutation in the lptI gene involved in the biosynthesis of 3-methyl-Glu 12 (3mGlu 12 ), and all recombinants produced novel lipopeptides. One of the compounds displayed very good antibacterial activity in the presence of bovine surfactant, which interacts with daptomycin or A54145E to inhibit their antibacterial activities. (Figure 1 ) is a complex of calcium-dependent lipodepsipeptide antibiotics produced by Streptomyces fradiae NRRL 18160. 1,2 A54145 has a cyclic depsipeptide ring containing 10 amino acids and an exocyclic tail of three amino acids, and it is similar in overall structure to daptomycin. Like A21987C and daptomycin, 3,4 the Nterminal Trp 1 of the exocyclic peptide is coupled to long-chain length fatty acids, the most common being iso-decanoyl, n-decanoyl and anteiso-undecanoyl in A54145 factors. 1,2 A54145 factors also vary at positions 12 and 13, in which different factors have different combinations of Glu 12 , L-3-methyl-Glu 12 (3mGlu 12 ), Ile 13 , or Val 13 . The most prevalent factors produced during the S. fradiae fermentation are shown in Figure 1 . Typically, A54145 factors containing Glu 12 accumulate early in fermentation and those containing 3mGlu 12 accumulate later, with final yields of about 60% of factors containing Glu 12 . 1 The study by Boeck et al. 5 demonstrated that the distribution of A54145 factors can be manipulated by adding certain amino acids or lipids to the fermentation. For instance, feeding L-Ile, enriched for factors containing Ile 13 from 89 to 98%, whereas feeding L-Val (which inhibited overall lipopeptide production by about 70%) enriched for compounds containing Val 13 from 11 to 56%, almost exclusively in
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A54145 (
) is a complex of calcium-dependent lipodepsipeptide antibiotics produced by Streptomyces fradiae NRRL 18160. 1, 2 A54145 has a cyclic depsipeptide ring containing 10 amino acids and an exocyclic tail of three amino acids, and it is similar in overall structure to daptomycin. Like A21987C and daptomycin, 3, 4 the Nterminal Trp 1 of the exocyclic peptide is coupled to long-chain length fatty acids, the most common being iso-decanoyl, n-decanoyl and anteiso-undecanoyl in A54145 factors. 1,2 A54145 factors also vary at positions 12 and 13, in which different factors have different combinations of Glu 12 , L-3-methyl-Glu 12 (3mGlu 12 ), Ile 13 , or Val 13 . The most prevalent factors produced during the S. fradiae fermentation are shown in Figure 1 . Typically, A54145 factors containing Glu 12 accumulate early in fermentation and those containing 3mGlu 12 accumulate later, with final yields of about 60% of factors containing Glu 12 . 1 The study by Boeck et al. 5 demonstrated that the distribution of A54145 factors can be manipulated by adding certain amino acids or lipids to the fermentation. For instance, feeding L-Ile, enriched for factors containing Ile 13 from 89 to 98%, whereas feeding L-Val (which inhibited overall lipopeptide production by about 70%) enriched for compounds containing Val 13 from 11 to 56%, almost exclusively in factor F (containing Glu 12 ). Feeding either of these amino acids also dramatically shifted the distribution of lipid side chains attached to the core.
The fatty-acid side chains of the A54145 factors can be removed by a deacylase produced by Actinoplanes utahensis, 6 thus providing a means to generate the peptide core as a starting material for chemical acylations with different fatty acids. 7 Several semisynthetic derivatives were tested for antibacterial properties and acute toxicity in mice. 8 The most potent natural factors (B, B 1 and E), contain 3mGlu 12 and Ile 13 , but the LD 50 for A54145B is low at only 28 mg kg À1 . The natural factors containing Glu 12 and Ile 13 had about twofold lower antibacterial activities, but were substantially less toxic (for example, LD 50 4500 mg kg À1 for A54145A). A semisynthetic derivative of the A54145A core peptide containing an undecanoyl side chain had improved antibacterial activities in vitro (MICs ranging from 0.5 to 4 mg ml À1 for different Staphylococcal and Streptococcal strains), in vivo efficacy against Streptococcus pyogenes in a mouse protection assay (ED 50 ¼1.6 mg kg À1 ), and low toxicity (LD 50 4500 mg kg À1 ). 8 Daptomycin has been approved for the treatment of complicated skin and skin structure infections caused by Gram-positive bacteria, 9 and for the treatment of bacteremia and right-sided endocarditis caused by Staphylococcus aureus, including strains resistant to methicillin (MRSA). 10 One shortcoming of daptomycin is its lack of efficacy in community-acquired pneumonia. 11 The poor efficacy in lung tissue appears to be caused by the sequestration of daptomycin in the lung surfactant. 12 To address this issue, derivatives of daptomycin were generated by modifying the lipid side chain or the d-amino group of ornithine by medicinal chemistry, 13, 14 and by modifying the core peptide by combinatorial biosynthesis. 15, 16 Although improvements in antibacterial activity in the presence of surfactant relative to daptomycin were observed, none of the compounds were active enough to carry forward into clinical studies.
As part of the combinatorial biosynthesis program, the lpt gene cluster dedicated to the biosynthesis of A54145 was cloned and sequenced, 17 the complete pathway was localized on a bacterial artificial chromosome (BAC) vector and expressed in heterologous streptomycete hosts. 18 In addition, an ectopic transcomplementation system was developed to engineer the A54145 biosynthetic gene cluster in Escherichia coli using l-Red-mediated recombination, conjugation from E. coli mediated by oriT from plasmid RP4, and site-specific integration of engineered plasmids into bacteriophage fC31 and fBT1 attB sites. 18 Using this system, the A54145 nonribosomal peptide synthetase (NRPS) genes were genetically engineered to generate hybrid lipopeptides by module exchange. 19 A mutant, defective in the lptI gene was engineered and confirmed that its gene product is the methyltransferase involved in the biosynthesis of 3mGlu 12 , resulting in the production of only the Glu 12 -containing factors. 18 It is believed that LptI uses a similar mechanism, as the homologous GlmT methyltransferase from Streptomyces coelicolor converting a-ketoglutarate to the (2S,3R)-3-methylglutamate intermediate that is further converted to 3mGlu by a transaminase from primary metabolism. 20 When fermented in DSF medium with isoleucine, the strain produced 40.5 g l À1 of A54145D. 18 In addition to 3mGlu 12 , the A54145 factors have three other modified amino acids, L-hydroxy-Asn (hAsn 3 ), sarcosine (Sar 5 ) and L-methoxy-Asp (moAsp 9 ). The biosynthesis of Sar is encoded in the lptA NRPS gene as a methyltransferase (M) domain that converts Gly to Sar, but the other amino acid modifications are believed to be catalyzed by individual oxygenases and an O-methyltransferase. 17 In the present study, we constructed strains containing combinations of deletions of lptJ, lptK and lptL genes encoding the three enzymes predicted to be involved in the biosynthesis of hAsn and moAsp, and analyzed the lipopeptides produced during fermentation to confirm the gene functions. We combined these deletions with the lptI deletion, and with plasmids containing combinations of the lpt genes to generate a series of novel lipopeptides. The antibacterial activities of the A54145 derivatives were determined in the presence and absence of bovine pulmonary surfactant, of which, one compound displayed very good antibacterial activity.
MATERIALS AND METHODS
Strains, plasmids, media, growth conditions and conjugation
The strains and plasmids used in this study are shown in Table 1 . Luria-Bertani broth or Luria-Bertani agar 21 was used for the growth of E. coli strains at 371C, except when the temperature-sensitive plasmid pKD119 22 was present. When appropriate, media were supplemented with ampicillin (Amp; 100 mg ml À1 ), apramycin (Am; 100 mg ml À1 ), chloramphenicol (Cm; 25 mg ml À1 ), tetracycline (Tc; 12.5 mg ml À1 ), neomycin (Nm; 50 mg ml À1 ), spectinomycin (Spc; 50 mg ml À1 ) or hygromycin B (Hm; 50 mg ml À1 ). The media and growth conditions for S. fradiae and the method for conjugation of plasmid DNA from E. coli to S. fradiae were as described. 18 S. fradiae strains were grown in CSM broth or on mR2YE agar, and when appropriate supplemented with trimethoprim (Tmp; 50 mg ml À1 ), neomycin (10 mg ml À1 ), apramycin (10 mg ml À1 ) or hygromycin B (150 mg ml À1 ).
Truncation of the lpt cluster with t o terminator-Amp R cassette
The t o terminator-Amp R cassette was PCR amplified from pDA1836 and the l-Red-mediated recombinations were carried out as described. 18, 22 The PCR product was made using primers P1 (5¢-GGGTAACGCCAGGGTTTTCCC AGTCACGACGTTGTAAAACGACGGCCATGTGTAGGCTGGAGCTGCTTC-3¢, italicized letters indicate primer binding sites for pDA1836) and P2 (5¢-CGCCCGCACCGACGAACTCCTGGCCGCCCACAAAGTGCTGTTCCTCAG AACGGATAACAATTTCACACAGGA-3¢) to delete lptJ and downstream DNA by recombination from the integrative lpt cluster BAC pDA2002 to generate pDA2060. Additional PCR templates made in this manner were used to delete lptK (P1 and P3 (5¢-TCGGGGCCAACATCGGCATGTTCACCCTCTTCGT ACGCTCGGAACGATATATTAAGCGGATAACAATTTCACACAGGA-3¢)) and lptL (P1 and P4 (5¢-GGTCCCCCACCTCCCGGAGAAACAGCATGGAACCC GAGAACACCTTCACCCTGGATAACAATTTCACACAGGA-3¢)), as well as downstream DNA, to generate pDA2074 and pDA2076, respectively, from pDA2002.
Construction of integrative, ermE*p containing BACs expressing multiple lpt genes Derivatives of pCB01 with the fBT1 cassette and strong constitutive ermE* promoter inserted immediately upstream of the start codon of lptK or lptL were constructed by l-Red-mediated recombination as described previously. 18 The initial 0.3 kb of the lptK gene was PCR amplified from pCB01 using the primers P5 (5¢-CTAGAATTCACATATGACCATCGCCCTCGC-3¢, underlined letters indicate restriction sites) and P6 (5¢-CAATCTAGACCGGATAGTGGGT GAACTCG-3¢) and cloned adjacent to the fBT1 cassette-ermE* promoter to generate pDA1860. The B6 kb NheI fragment containing the BAC flanking region-fBT1 cassette-ermE*p::lptK was excised from the plasmid and used for l-Red-mediated recombination into pCB01 to generate the BAC pJR2012. Figure 1 The structure of the A54145 factors normally produced by S. fradiae. Amino acid modifications to the lipopeptide that are of interest to this study are highlighted in gray.
The resulting lptKLI expression plasmid was functionally validated by complementation of the DA1333 strain (DlptKLI) to generate DA1449. Similarly, 0.3 kb from the start of the lptL gene was PCR amplified from pCB01 using the primers P7 (5¢-AACCATATGGAACCCGAGAACACCTTCAC-3¢) and P8 (5¢-TGTTCTAGACGGGAAGGTTGCGCAGGAGC-3¢) and cloned adjacent to the fBT1 cassette-ermE* promoter to generate pDA1862. The B6 kb fragment containing the flanking region-fBT1 cassette-ermE*p::lptL was excised from the plasmid with NheI digestion and used for l-Red-mediated recombination into pCB01 to generate the BAC pJR2015. The lptLI expression plasmid was functionally validated by complementation of the DA1336 strain (DlptLI) to generate DA1621.
Construction of single lpt gene complementation plasmids
A DNA fragment containing the Spc R coding region was PCR amplified with the primers P9 (5¢-CTAGAATTCACATATGAGGGAAGCGGTGATCG-3¢) and P10 (5¢-CAATCTAGAGTCTTCCCCAGCTCTCTAAC-3¢) and ligated into NdeI and XbaI-digested ermE* promoter expression vector pDA1652, 18 to generate pDA2112. The ermE*p::Spc R expression cassette flanked by the t o and fd terminators was PCR amplified with primers P11 (5¢-TCGGGTTAAC TGCGGGGTCGTCAAC-3¢) and P12 (5¢-TGAGCGGCCGCAAGCTTACT GAGCAACGCGAAGGC-3¢) and digested with HpaI and NotI. The digested PCR product was inserted into pRT802, 23 digested with NotI and EcoRV to create pDA2113.
The t o terminator-Cm R cassette was generated by replacing the Amp R gene in pDA1836. 18 with the Cm R gene to generate pDA1842. The Cm R gene was PCR amplified from pCB01 using the primers P13 (5¢-ATCGCGGCCGCACGGAA GATCACTTC-3¢) and P14 (5¢-CGCAAGCTTCGCCGTCGACCAATTCTC ATG-3¢), digested with NotI and HindIII and ligated with pDA1836 digested with NotI and HindIII to remove the Amp R gene.
The lptL gene was amplified from pCB01 using primers P15 (5¢-AACCA TATGGAACCCGAGAACACCTTCAC-3¢) and P16 (5¢-CGCTCTAGAGT CAGGTCCACGCCGGCGAG-3¢) and digested with NdeI and XbaI. The lptL gene was inserted into pDA2113 digested with NdeI and HindIII (removes Spc R and t o terminator) as part of a three-piece ligation with the t o terminator-Cm R cassette, which was removed from pDA1842 as a HindIII and XbaI fragment, to produce pDA2117. The introduction of the t o terminator-Cm R cassette was required because the conjugation helper plasmid in ML22 is also Nm R . The lptL expression plasmid was functionally validated by complementation of the DA1336 strain (DlptLI) to generate DA1470.
In a similar manner, pDA2129 was created by inserting the lptI gene amplified from pCB01, using primers P17 (5¢-GAGGAATTCACATATG CACCGGCGGGAAC-3¢) and P18 (5¢-CAATCTAGACACTCCTCTGCGGG CAGTC-3¢) and the Cm t o terminator cassette digested with the appropriate restriction enzymes into pDA2113. The lptI expression plasmid was functionally validated by complementation of the DA613 DlptI mutant to generate DA1491.
Fermentation, measurement of lipopeptide production and purification of lipopeptides
Engineered strains of S. fradiae were fermented in DSF production medium, 1 supplemented with 0.79% (w/v) of L-Ile (DSF-Ile). 18 Addition of Ile to the optimized media drives production towards factors containing Ile 13 and anteiso-undecanoyl side chains derived from precursors generated by Ile catabolism. Production of A54145 factors and novel lipopeptides was monitored by HPLC and LC-MS as described. 18 Production of A54145 factors in liquid culture or on agar plates can also be assessed by a bioactivity assay using S. aureus ATCC 29213 with 5 mM CaCl 2 . 18 Engineered strains producing novel lipopeptides were scaled up to 5 l of DSF-Ile in multiple shake flasks and centrifuged culture supernatant was purified by column chromatography using HP20 resin and semipreparative HPLC as described. 24 Only the major lipopeptide produced in DSF-Ile media, containing Ile 13 and anteiso-undecanoyl side chain was purified and characterized. LC-MS-MS analysis of select lipopeptides was carried out as described. 24 
Antibacterial activity assay for lipopeptides
Minimum inhibitory concentrations were determined by broth microdilution using Mueller-Hinton broth supplemented with 50 mg l À1 Ca 2+ (MHBc). Cultures were incubated at 371C with rotation (200 r.p.m.). Susceptibility of S. aureus ATCC 29213 for purified lipopeptides was determined in MHBc media with or without supplemented 1 % (v/v) bovine pulmonary surfactant (Survanta; Abbott Laboratories, Columbus, OH, USA). 12 Bioinformatics analyses of putative Lpt proteins BLASTP analysis 25 of translated putative protein sequences was carried out at the NCBI website (http://www.ncbi.nlm.nih.gov/). c Lpt genes present on plasmids are in bold. Genes in the lpt pathway are not sequential so lptEF-I is actually lptEFABCDGHJKLMNPI and is an example of the shorthand used for this lengthy set of genes.
RESULTS
Engineering and characterization of mutants blocked in the biosynthesis of hAsn 3 and moAsp 9, and assignment of lptJ, lptK and lptL gene functions S. fradiae A54145 normally produces a mixture of lipopeptide factors containing Glu or 3mGlu at position 12, Ile or Val at position 13, coupled with any of three lipid side chains (Figure 1 ). In a previous study, it was shown that production of the factors containing 3mGlu 12 can be eliminated by deleting the lptI methyltransferase gene in the biosynthetic gene cluster. 18 Furthermore, factors A54145D and A54145E (containing Ile 13 and with anteiso-undecanoyl side chains) can be greatly enriched by supplementing the fermentation medium with L-Ile. Bioinformatic analyses of the region downstream of the NRPS gene lptD (Figure 2 ) initially suggested that lptK, lptL and lptI genes are involved in amino acid modification, with the lptJ gene possibly involved in gene regulation based on an incorrect annotation of syrP (see below), and the lptM, lptN and lptP genes involved in resistance or transport. 17 These analyses provided a strong rationale for the determination of lptJ, lptK and lptL gene functions by genetic modification, namely deletion and complementation.
Using the tools and techniques developed for S. fradiae and described in Alexander et al., 18 a set of plasmids deleted for lptI, lptLI, lptKLI and lptJKLI was constructed by l-Red-mediated recombination. The downstream ends of the lpt gene cluster containing BACs were deleted and replaced with the t o terminator-Amp R cassette ( Figure 2 ). The recombinant BACs were introduced into the lpt cluster deletion mutant DA1187 (DlptEF-I::tsr) and the engineered strains were fermented in DSF-Ile medium to characterize the lipopeptide(s) produced, with a focus only on the major lipopeptides produced containing Ile 13 and anteiso-undecanoate side chains. Host strains, BACs, plasmids, their relevant genotype with respect to the lptJKLI genes for the engineered strains and the resulting lipopeptide products are summarized in Table 2. A54145E, which contains hAsn 3 , moAsp 9 , 3mGlu 12 and an anteisoundecanoyl side chain, and has a mass ion of 1672.7, was used as the fully modified lipopeptide reference standard. Strain DA1243 (DlptI) produced A54145D, which has a mass ion of 1658.7 differing from A54145E by the loss of the Me group at Glu 12 and consistent with previous work. 18 Strain DA1336 (DlptLI) produced the major lipopeptide (CB-182,325), which had a mass ion of 1642.7, consistent with the loss of an additional hydroxyl group, indicating that lptL encodes one of the two hydroxylases needed. As this strain did not produce a compound lacking the methoxy group, lptL likely encodes the Asn 3 hydroxylase. Strain DA1333 (DlptKLI) produced CB-182, 349, with a mass ion of 1628.7, consistent with the loss of an additional Me group. Therefore, lptK likely encodes the methyltransferase that converts hAsp 9 to moAsp 9 . Strain DA1327 (DlptJKLI) produced CB-182,348 with a mass ion of 1612.7, consistent with the loss of an additional hydroxyl group, indicating that lptJ probably encodes the Asp 9 hydroxylase.
Complementation of lpt mutants to generate novel lipopeptides By introducing specific genes or gene sets into the mutants, it was possible to generate an expanded set of novel lipopeptides and further confirm the gene function assignments described above. Plasmid pDA2117 expressing the lptL gene was introduced into the DA1327 background giving DA1484, which produced CB-182,333, with a mass ion of 1628.7 (Table 2 ). When introduced into the DA1333 background, it generated DA1453, which produced CB-182,350, with a mass ion of 1644.7. The increase of 16 mass units to the parental lipopeptide is consistent with lptL encoding the Asn 3 hydroxylase.
The plasmid pDA2129 expressing the lptI methyltransferase gene was introduced into the three deletion mutants described to give DA1489, DA1459 and DA1467, which produced three novel lipopeptides CB-182,390, CB-182,597 and CB-182,363, respectively. As expected, the mass of each of the three novel lipopeptides increased by 14 mass units from the parental lipopeptide consistent with its function as the Glu 12 methyltransferase. 18 Introduction of the pJR2015 BAC vector, containing the lptL and lptI genes, into DA1333 generated strain DA1627, which produced a novel lipopeptide with a mass ion of 1658.7, a 30 mass unit increase compared with the parental lipopeptide. Introduction of pJR2012 BAC vector with the lptK, lptL and lptI genes into DA1327 generated strain DA1553 and resulted in production of CB-182,443 with a 30 mass unit increase over the parental lipopeptide. An identical lipopeptide was produced when pJR2015 was introduced into DA1327, consistent with lptL encoding the Asn 3 hydroxylase and lptI encoding the Glu 12 methyltransferase, but suggests a lack of functional activity from the lptK methyltransferase present on the pJR2012 BAC on the hAsn 3 , Asp 9 and 3mGlu 12 lipopeptides produced by DA1553. 
Novel lipopeptide antibiotics DC Alexander et al
The engineered strains produced novel lipopeptides at titers that ranged from 32 to 360 mg ml À1 (Table 2 ). These titers were sufficient for compound isolation from the 5 l scale-up fermentations for further characterization. (Figure 3b ). As summarized in Figure 3a , MS-MS spectra of 1B4 provided limited but distinct product ions from y 10 to y 12 along with their corresponding water-loss peaks. The assigned three fragments y 12 , y 11 , y 10 confirmed the side-chain amino acid sequences of 1 and 2 as anteiso-undecanoyl-Trp-Glu-hAsn and 3 and 4 as anteisoundecanoyl-Trp-Glu-Asn, respectively. Furthermore, the amino acid sequences of 1B4 were determined by the analyses of the MS-MS data from 1aB4a (m/z 1676.8, 1646.8, 1630.7, 1646.8 [M+H] + , respectively), which were produced by hydrolysis of 1B4 with lithium hydroxide. As shown in Figure 3b , experimental values of yn and bn agreed with their respective theoretical fragment ions. Therefore, the amino acid sequences of compound 1B4 were strongly supported by the linear hydrolysates 1a-4a, as anteiso-undecanoyl-Trp-Glu-hAsnThr-Sar-Ala-Asp-Lys-moAsp-Gly-Asn-Glu-Ile, anteiso-undecanoylTrp-Glu-hAsn-Thr-Sar-Ala-Asp-Lys-Asp-Gly-Asn-Glu-Ile, anteisoundecanoyl-Trp-Glu-Asn-Thr-Sar-Ala-Asp-Lys-Asp-Gly-Asn-Glu-Ile and anteiso-undecanoyl-Trp-Glu-Asn-Thr-Sar-Ala-Asp-Lys-hAsp-GlyAsn-Glu-Ile, respectively. The MS-MS data are consistent with our gene function predictions such that CB-182,333 produced by DA1484 (DlptJKI), which expresses LptL, hydroxylates Asn 3 and CB-182,349 produced by DA1333 (DlptKLI), which expresses LptJ, and hydroxylates Asp 9 .
LC-MS-MS characterization of select novel lipopeptides to confirm LptJ and LptL functions
Antibacterial properties of A54145 derivatives
The antibacterial properties of A54145 derivatives against S. aureus in the presence and absence of 1% bovine surfactant are shown in Table 3 . As controls, daptomycin and its close analog CB-181,220, which has an anteiso-undecanoyl rather than an N-decanoyl side chain, were compared with the A54145 derivatives. Both daptomycin and CB-181,220 had MICs of 0.5 mg ml À1 in the absence of surfactant and 64 mg ml À1 in the presence of 1% surfactant. Potency of CB-182, 130, a Glu 12 analog of CB-181,220 was significantly higher (16-fold higher MIC or 8 mg ml À1 ) than daptomycin or CB-181,220 in the absence of surfactant but retained activity in the presence of 1% surfactant (16 mg ml À1 ). A54145E had an MIC of 1 mg ml À1 in the absence of surfactant, but the MIC in the presence of 1% surfactant was increased by 32-fold. Removal of the Me group from Glu 12 (A54145D) resulted in only a twofold increase in MIC (2 mg ml À1 ) in the absence of surfactant, and an eightfold reduction in MIC in the presence of surfactant (4 mg ml À1 ) relative to A54145E. A similar result was obtained by removing the methoxy group from Asp 9 (CB-182, 443). Removal of the methoxy group from Asp 9 and the hydroxyl group at Asn 3 yielded CB-182,390, which had MICs of 2 mg ml À1 in the presence or absence surfactant. Other combinations of hypomodification of Asn 3 , Asp 9 and Glu 12 gave antibiotics with less favorable MIC profiles ( Table 3) .
The results from inactivating the various amino acid modification enzymes indicate that the antibacterial properties of A54145 can be altered by simply changing the modified amino acid composition. Whereas the fully modified A54145E was the most active antibiotic, several compounds lacking one or two amino acid modifications were nearly as active as A54145E in the absence of surfactant and more active in the presence of surfactant. The best compound (CB-182,390) displayed only a twofold in increase in MIC (2 mg ml À1 ) over A54145E in the absence of surfactant, with no change in potency in the presence of surfactant (2 mg ml À1 ).
Bioinformatic analysis of the lptJKL gene products LptL showed highest sequence similarity (47%) to AsnO that hydroxylates Asn during the lipopeptide CDA biosynthesis. 26, 27 Furthermore, LptL has a binding pocket for the oxygenation of Asn identical to that of AsnO, EQNHENDHR (Table 4) . 27 LptL and AsnO homologs with amino acid sequences ranging from 47 to 60% identities were observed in Saccharopolyspora erythraea, Streptomyces scabies, Streptomyces sp. SPB78, Streptomyces sp. SPB74 and Streptomyces sp. C, all of which have amino acid binding pockets identical to those of AsnO and LptL (Table 4) . S. coelicolor and Streptomyces lividans encode AsnO proteins of identical sequence, and also encode AsnO/LptL homologs with binding pockets differing in one amino acid from the AsnO/LptL pocket (Table 4) . Although LptJ encodes a hydroxylase that converts Asp 9 to hAsp 9 , BLASTP analysis indicated that it has no sequence similarity to LptL. The top BLASTP hits were to a conserved hypothetical protein from Streptomyces clavuligerus (ZP_050077403; 63% identity) and a SyrPlike protein from Streptomyces avermitilis (NP_824815; 63% identity). It also showed 33% identity with the SyrP L-Asp hydroxylase from Pseudomonas syringae. 28 LptJ defines the first L-Asp hydroxylase encoded by a secondary metabolite biosynthetic gene cluster in an actinomycete, although it has been shown that asnO can be modified by site-specific mutagenesis to encode an enzyme that will hydroxylate Asp. 29 BLASTP analysis of LptK was consistent with it functioning as a methyltransferase. However, the only BLASTP hit above 31% identity Novel lipopeptide antibiotics DC Alexander et al was to a putative methyltransferase from Streptomyces griseus (BAG17399; 45% sequence identity).
DISCUSSION
The cyclic lipopeptide antibiotic A54145 complex of related factors is distantly related to the clinically important antibiotic daptomycin, and several of the factors demonstrate good antibacterial activities against Gram-positive pathogens. 1, 8 The most active compounds containing 3mGlu 12 were toxic to mice, whereas those containing Glu 12 were about 20-fold less toxic and displayed only twofold lower antibacterial activities. 8 In a recent study, we generated strains deleted for the lptI gene, and the mutants produced 40.5 g l À1 of the Glu 12 -containing A54145D when fermentations were supplemented with L-Ile. 18 In the present study, we generated a series of S. fradiae strains deleted for different combinations of the lptJ, lptK, lptL and lptI genes. By analyzing the products of the engineered strains, we were able to deduce the functions of the lptJ, lptK and lptL genes, as Asp 9 hydroxylase, hAsp 9 methyltransferase and Asn 3 hydroxylase, respectively, and further confirmed the function of the lptI gene as the Glu 12 methyltransferase. The genetic engineering tools developed for S. fradiae were well suited for a combinatorial biosynthesis approach to assign gene function and generate a series of novel lipopeptides. Fermentation of the engineered strains in DSF-Ile media shifted production predominantly to the factors containing Ile 13 and anteiso-undecanoyl side chains, which simplified HPLC and LC-MS analysis of the fermentation broths and purification of the novel A54145 factors. We chose to pursue the purification and characterization of only A54145D or A54145E analogs (Ile 13 and the anteisoundecanoyl side chain) because of the concentration advantage afforded by the Ile supplementation and increased chromatographic separation of these lipopeptides resulting in higher-yielding purifications. Characterization of novel lipopeptides with the different lipid side chains would have increased the number of analogs generated, but the MIC data 8 did not suggest significant differences among the different side chains to warrant purification of the remaining lipopeptides. Also in support of this decision to focus only on the major lipopeptide, we had confirmed the previous observation that Val 13 containing lipopeptides A54145F had inferior MICs in comparison with the Ile 13 counterpart (Counter et al. 8 ; and data not shown). With all analogs having the same lipid side chain, direct antibacterial activity comparison among the hybrid lipopeptides was possible.
It is noteworthy that even the strain deleted for all four genes produced lipopeptide antibiotics (CB-182,348; Table 2 ). This means that the NRPS enzymes can process Asn or hAsn at position 3, Asp, hAsp or moAsp at position 9 and Glu or 3mGlu at position 12. This astonishing flexibility was exploited to generate many novel compounds, discussed below. It is also noteworthy that the specific amino acid modifications were localized to the L-isomers of Asn, Asp and Glu at positions 3, 9 and 12, respectively, even though A54145E has a D-Asn, L-Asp and D-Glu residues at positions 11, 7 and 2, respectively. This site specificity of amino acid modifications is particularly relevant in light of the observation that the amino acid binding pockets for hAsn 3 and moAsp 9 are indistinguishable from those for Asn 11 and Asp 7 , respectively. 17 Further characterization of AsnO and its functional homolog LptL and their interactions with their respective NRPS proteins may shed light on the mechanism of relaxed amino acid binding specificity at positions 3, 9 and 12 for modified amino acids, coupled with the apparent stringent amino acid binding specificity at positions 2, 7 and 11.
Addition of pJR2012 (lptKLI) or pJR2015 (lptLI) to DA1327 (DlptJKLI) generated strains that produced the hAsn 3 , Asp 9 and 3mGlu 12 lipopeptide CB-182,443. It is not a lack of function from the lptK methyltransferase present on the pJR2012, but rather lptK function requires the presence of lptJ to generate the hAsp 9 substrate necessary for lptK O-methylation. This sequential order was confirmed in an additional strain engineering experiment using plasmids expressing only lptJ or only lptK or lptJ and lptK together in the DA1327 background (data not shown). The strain containing the lptK plasmid alone produced only the parental lipopeptide, whereas lptJ alone and lptJK together produced lipopeptides with 16 and 30 mass unit increases to the parental lipopeptide, confirming lptK action on the lptJ catalyzed hAsp 9 substrate. These data further confirm that LptJ converts Asp 9 to hAsp 9 , the obligatory substrate for the LptK O-methyltransferase action.
Titers of the novel lipopeptides ranged from 10 to 75% of the 462 mg ml À1 of A54145D produced by DA1243. The majority of the novel lipopeptide producing strains lacked the LptM and LptN transporter pair, which are clearly not essential for antibiotic export, but may aid in optimal export of antibiotic. The lptM and lptN genes are only present in strains DA1243, DA1553 and DA1627. Strain DA1453 produces the hAsn 3 , hAsp 9 , Glu 12 (CB-182,350) at B75% of the A54145D titers, whereas hAsn 3 , Asp 9 , Glu 12 (CB-182,333) is produced at only B25% by strain DA1484 and Asn 3 , moAsp 9 , Glu 12 (CB-182,325) is produced at only B17% by strain DA1336. This type of direct comparison would be more conclusive with individual in-frame deletion mutants for each gene, but it does suggest 12 , which results in good potency but uniquely displayed good activity in the presence of 1% surfactant. CB-182,390 (Asn 3 , Asp 9 and 3mGlu 12 ) was targeted for further investigation, including extensive chemical analyses, including amino acid quantitation, tandem LC-MS-MS analysis and 2D-NMR to confirm the structure. 24 Potent antibacterial activity depends on the presence of modified amino acids, making total peptide synthesis or chemoenzymatic synthesis, 30 utilizing proteinogenic amino acids undesirable approaches to generate A54145 analogs. As chemical synthesis of the chiral modified amino acids at the necessary scale for SAR studies is not practical, combinatorial biosynthesis 19 remains the most effective method to generate potent novel lipopeptides.
In a separate study, the M domain was deleted from the Sar 5 module to generate an A54145D analog (CB-182,391) containing Gly 5 , which was eightfold less active than A54145D in the presence or absence of surfactant with MICs of 16 and 32 mg ml À1 , respectively (S Doekel and P Brian, unpublished). This indicates that Sar 5 is also important for overall activity of A54145 lipopeptides.
The study by Strieker et al. 27 have shown that AsnO converts the free L-Asn to L-hAsn before incorporation into the growing peptide. According to their model, L-hAsn binds to the adenylation (A)-domain of the CA hAsn9 TE module of CdaPS2, in which it is converted to D-hAsn and incorporated into the growing peptide chain. The AsnO protein was crystallized, and the catalytic binding pocket for L-Asn has been defined as a 10 letter code: EQNHENDHR at positions 125, 144, 146, 155, 157, 158, 241, 287 and 305. 27 The LptL protein has an identical L-Asn catalytic binding pocket displaced by eight amino acids relative to AsnO, and starting at position E117. Therefore, even though the lptL and asnO genes and their protein products have diverged considerably (47% identical amino acids), they have conserved the L-Asn binding pocket 100%. This supports the notion that although these enzymes have orthologous catalytic functions, they have likely diverged for a second non-orthologous function. 31 One possible non-orthologous function is binding to different NRPS enzymes at specific modules to provide L-hAsn in situ on demand during peptide assembly. 31 This model predicts amino acid sequence divergence in regions of the proteins involved in protein-protein interactions, and also provides a mechanism to sequester L-hAsn from the cytoplasmic amino acid pools that can be drawn on for protein biosynthesis. It also explains the absence of incorporation of hAsn at position 11.
There are currently over 20 streptomycete and many other actinomycete genome sequences in GenBank. There are homologs to LptL and AsnO showing 447% amino acid identities over nearly the entire proteins in seven streptomyctes and in Saccharopolyspora erythraea (Table 4) . Their high amino acid sequence similarities suggest that some or all may function as L-Asn oxygenases.
BLASTP analysis indicated that LptJ is unrelated to the LptL, but it displays high sequence similarities with only two proteins, a SyrP-like protein from S. avermitilis (62% identity) and a conserved hypothetical protein from S. clavuligerus (62% identity). LptJ shows 33% sequence identity with SyrP from P. syringae, an enzyme that has been shown to hydroxylate L-Asp tethered as the protein-bound S-pantetheinyl thioester on an NRPS module involved in syringomycin biosynthesis to produce L-threo-3-OH-Asp. 28 If LptJ hydroxylates L-Asp in a similar manner during A54145 biosynthesis, it might account for the specificity of hydroxylation at Asp 9 and not Asp 7 . LptJ defines functionally the first of the SyrP-like L-Asp hydroxylases in actinomycetes, and the high sequence identities to the two related proteins from genome sequencing projects suggests that they may also function as L-Asp hydroxylases. Bioinformatics had originally predicted LptJ to have a role in gene regulation based on its initial annotation. 15 Biochemical characterization of SyrP confirmed its actual role in syringomycin biosynthesis is as an Asp hydroxylase, 28 which is consistent with our prediction for the homologous LptJ in this study.
BLASTP analysis of LptK indicated that this protein class is even more obscure that LptJ. LptK showed 45% sequence identity to a putative methyltransferase from S. clavuligerus and 45% identity to a sequence (likely a methyltransferase) embedded in a NRPS from Pseudomonas aeruginosa strains. The uniqueness of LptK may not be surprising as the moAsp in A54145 represents the only known moAspcontaining natural product that we are aware of. The functional assignment of the lpt genes described herein should help in the annotation of cryptic secondary metabolite pathways that are being rapidly discovered by genome mining.
